Teva Pharmaceutical Industries And Samsung Bioepis Partner To Commercialize OPUVIZ Aflibercept Biosimilar In Canada
Benzinga Newsdesk 3 months ago
BiotechGeneralNews
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE: TEVA) and Samsung Bioepis Co., Ltd. today announced that the companies have entered into a license and commercialization agreement for OPUVIZ® (aflibercept), a
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE: TEVA) and Samsung Bioepis Co., Ltd. today announced that the companies have entered into a license and commercialization agreement for OPUVIZ® (aflibercept), a biosimilar referencing Eylea®1 (aflibercept), in Canada.
Under the agreement, Samsung Bioepis is responsible for registration and manufacture of the products, while Teva Canada (a subsidiary of Teva Pharmaceutical Industries Ltd.) is responsible for commercialization.